Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

NCT04765449 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

DRUG: Cytotoxic T Lymphocytes

Sponsor

Thomas Jefferson University

Collaborators

[object Object]